First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today. Entero's common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ticker symbol of ENTO.
Entero Therapeutics, Inc.（前身爲第一波生物製藥公司）納斯達克股票代碼：ENTO）（“Entero” 或 “公司”）是一家臨床後期生物製藥公司，專注於胃腸道（GI）疾病的靶向非全身療法的開發，今天公佈了其新的公司名稱和網站。此次品牌重塑遵循了最近與ImmunoGenX的業務合併，反映了該公司專注於解決包括乳糜瀉在內的胃腸道健康領域未得到滿足的需求，而乳糜瀉的適應症目前尚無獲批准的藥物。Entero的普通股將於2024年5月17日在納斯達克資本市場開始交易，新的股票代碼爲ENTO。